Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Richardson, Peter J.; Griffin, Ivan; Tucker, Catherine M.; Smith, D. Casey; Oechsle, Olly; Phelan, Anne M.; Rawling, Michael J.; Savory, Edward; Stebbing, Justin

doi:10.1016/s0140-6736(20)30304-4

Cited by 1,262 publications

(1,205 citation statements)

References 5 publications

Supporting

Mentioning

1,145

Contrasting

Unclassified

Order By: Relevance

“…Some of these may be more resistant to viral mutation than lopinavir/ritonavir [133]. Stebbing et al suggested that baricitinib may reduce both the viral entry and inflammation [134].…”

Section: Treatment and Managementmentioning

confidence: 99%

The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

Yang

Peng

Wang

et al. 2020

Journal of Autoimmunity

872

858

View full text Add to dashboard Cite

COVID-19 pandemic, an unprecedented devastation, humanity needs an urgent cure to save the mankind from this deadly disease. Over six million people have been infected worldwide, with 6.3% reported deaths till date. SARS-CoV-2 virus, responsible for Novel Coronavirus (COVID-19) disease has been isolated recently and the vaccine's development is at nascent stage. At present, there are a few anecdotal evidences that anti-viral/anti-in ammatory/anti-malarial drugs can mitigate the disease. In the present study, we envision the potency of traditional Indian medicinal compounds that can be used as an effective drug. The viral SARS Coronavirus E protein plays a key role in virus life cycle and can be a potential drug target for the development of anti-SARS-CoV-2 drugs. Using the crystal structure of the CoVE protein, we performed virtual PyRX screening of Indian medicinal compounds which are reported to have e cacy in the treatment of some viral infections. Molecular docking studies were evaluated based on scores analysed by CavityPlus. The herbal compounds used were found to be more e cient in inhibiting the virus as compared to commercially available drugs. The results showed that β-boswellic acid and Glycyrrhizic acid possessed the best binding as a ligand with target molecule having binding a nity of-9.1 kcal/mol amongst eleven compounds screened. The study demonstrated that these are found to be strong SARS-CoV-2E protein inhibitors as they revealed compatible, near perfect dock in the overlapping region of functional viral protein pockets. These potential hit compounds can pave a way for designing of anti-viral therapeutics.

show abstract

“…Some of these may be more resistant to viral mutation than lopinavir/ritonavir [133]. Stebbing et al suggested that baricitinib may reduce both the viral entry and inflammation [134].…”

Section: Treatment and Managementmentioning

confidence: 99%

The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

Yang

Peng

Wang

et al. 2020

Journal of Autoimmunity

872

858

View full text Add to dashboard Cite

show abstract

“…Recently, mice models and clinical isolates were used to develop any therapeutic strategy against SARS-CoV-2 induced COVID-19 (46,47). In a similar study, artificial intelligence prediction was used to investigate the inhibitory role of the drug against SARS-CoV-2 (48). SARS-CoV-2 infected patients were also used to conduct randomized clinical trials (46,49,50).…”

Section: The Major Obstacle In Research Progressmentioning

confidence: 99%

COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses

Shereen

Khan

Kazmi

et al. 2020

Journal of Advanced Research

3,240

2,878

View full text Add to dashboard Cite

The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world. Genomic analysis revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir. The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery. In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV). We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak. glycoprotein of novel coronavirus is developed from a SARS-CoV (CoVZXC21 or CoVZC45) and a yet unknown . Nonetheless, to eradicate the virus, more work is required to

show abstract

“…Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms. 1,2 In our previous Correspondence to The Lancet, 3 we described how BenevolentAI's proprietary artificial intelligence (AI)-derived knowledge graph, 4 queried by a suite of algorithms, enabled identification of a target and a potential therapeutic against SARS coronavirus 2 (SARS-CoV-2; the causative organism in COVID-19). We identified a group of approved drugs that could inhibit clathrin-mediated endocytosis and thereby inhibit viral infection of cells (appendix).…”

Section: Covid-19: Combining Antiviral and Anti-inflammatory Treatmentsmentioning

confidence: 99%

COVID-19: combining antiviral and anti-inflammatory treatments

Stebbing

Phelan

Griffin

et al. 2020

The Lancet Infectious Diseases

Self Cite

1,005

951

View full text Add to dashboard Cite

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Cited by 1,262 publications

References 5 publications

The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses

COVID-19: combining antiviral and anti-inflammatory treatments

Contact Info

Product

Resources

About